EMA recommends 10 medicines for approval in October meeting22 October 2020 | By Victoria Rees (European Pharmaceutical Review)Ten medicines have been recommended for marketing authorisation and 10 extensions of indication have been suggested by the EMA.
EIB to support COVID-19 therapy with €24.5 million investment21 October 2020 | By Hannah Balfour (European Pharmaceutical Review)The European Investment Bank (EIB) will provide Immunic with up to €24.5 million to support the ongoing development of IMU-838, a potential COVID-19 therapy.
UK to establish human challenge studies for COVID-19 vaccines21 October 2020 | By Hannah Balfour (European Pharmaceutical Review)The UK government hopes to expedite the development of a COVID-19 vaccine by investing £33.6 million in the first phase of establishing human challenge trials.
Inhaled antibody treatment for COVID-19 shows success in pre-clinical trials20 October 2020 | By Victoria Rees (European Pharmaceutical Review)Researchers have developed a monoclonal antibody called AR-711 that is highly neutralising against COVID-19 in an inhaled formulation.
Repurposed drugs not effective treatment for hospitalised COVID-19 patients, WHO says20 October 2020 | By Victoria Rees (European Pharmaceutical Review)WHO has said that remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon had little or no effect when treating hospitalised patients with COVID-19.
COVID-19 pandemic to heighten sales of pharmaceutical spray drying20 October 2020 | By Victoria Rees (European Pharmaceutical Review)A new report has predicted that the COVID-19 pandemic will drive demand for pharmaceutical spray drying, boosting the market.
Study suggests dolutegravir is the optimal first-line HIV medication19 October 2020 | By Hannah Balfour (European Pharmaceutical Review)Researchers comparing dolutegravir to efavirenz suggest dolutegravir increases viral suppression and has similar rates of adverse events.
The FDA requires changes to NSAID labelling19 October 2020 | By Hannah Balfour (European Pharmaceutical Review)The FDA is requiring that the prescribing information for nonsteroidal anti-inflammatory drugs (NSAIDs) include warnings about potential foetal kidney problems if taken by women over 20 weeks pregnant.
Telstar’s centre in the UK consolidates its business growth with move to new higher-capacity modern installation19 October 2020 | By TelstarSpecialised in aseptic and containment barrier Isolation technology systems, Telstar UK has seen increased demand for its products from all across the life sciences sector has grown significantly in the past few years.
Bioanalytical testing services market to become a $4.5 billion industry19 October 2020 | By Hannah Balfour (European Pharmaceutical Review)A report found the rise in outsourcing, growing popularity of biologics and expanding acceptance of quality-by-design approaches would drive the market expansion.
SARS-CoV-2 vaccine safely induces an immune response in healthy volunteers16 October 2020 | ByThe Chinese COVID-19 vaccine candidate BBIBP-CorV elicited an antibody response in all recipients, according to preliminary Phase I/II trial data.
MHRA joins international regulatory consortium16 October 2020 | By Hannah Balfour (European Pharmaceutical Review)By joining the Access Consortium, the MHRA will work together with agencies from Australia, Canada, Singapore and Switzerland to expedite therapeutic product approvals.
NIAID trial to identify potential COVID-19 treatments for further development16 October 2020 | By Hannah Balfour (European Pharmaceutical Review)The adaptive ACTIV-5/BET study will test two monoclonal antibody therapies in hospitalised COVID-19 patients to establish if they warrant larger clinical trials.
US FDA approves the first Ebola virus treatment – Inmazeb15 October 2020 | By Hannah Balfour (European Pharmaceutical Review)The US Food and Drug Administration (FDA) has approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) for the treatment of Zaire ebolavirus infection in adults and children.
First patient dosed in COVID-19 vaccine tablet clinical trial14 October 2020 | By Victoria Rees (European Pharmaceutical Review)A Phase I clinical trial to test VXA-CoV2-1, an oral tablet COVID-19 vaccine candidate, has been initiated with the first patient dosed.
